EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

Casey R Vanderlip iD, Craig E L Stark

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Casey R Vanderlip und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology and Behavior, University of California Irvine, Irvine, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association, GHR Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Amyloid positivity does not reliably predict near‐term cognitive decline in preclinical Alzheimer's disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision. METHODS Baseline performance on a brief self‐administered digital battery was analyzed in 1146 amyloid beta (Aβ)+ and 538 Aβ− cognitively unimpaired older adults from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's/Longitudinal Evaluation of Amyloid Risk and Neurodegeneration studies. Unsupervised k ‐means clustering identified cognitive phenotypes. Survival models examined time to Preclinical Alzheimer Cognitive Composite decline and Clinical Dementia Rating (CDR) progression. Associations with tau positron emission tomography and plasma phosphorylated tau (p‐tau)217 were evaluated. RESULTS Four cognitive phenotypes emerged. One phenotype (18% of Aβ+ participants) showed the steepest cognitive decline, highest progression on the CDR, greater baseline medial temporal tau, and fastest neocortical tau accumulation over 4.6 years (hazard ratio [HR] for decline ≈ 2.9). Combining this phenotype with elevated plasma p‐tau217 identified a subgroup at markedly amplified risk (HR ≈ 4.5). DISCUSSION Digital cognitive phenotyping, especially when integrated with plasma biomarkers, identifies actionable risk heterogeneity and enables scalable precision prognostication in preclinical AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansFemaleAgedPhenotypeMaletau ProteinsDisease ProgressionPositron-Emission TomographyAmyloid beta-PeptidesRisk AssessmentNeuropsychological TestsProdromal SymptomsAged, 80 and overBiomarkersDigital Health

Stichwörter der Autor:innen

Alzheimer's diseaseblood biomarkersdigital cognitive assessmentsearly detectionprognosisrisk stratification

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • Department of Neurobiology and Behavior, University of California Irvine, Irvine, California, USA.

ORCID-Profile: Casey R Vanderlip

Förderung

  • NIA NIH HHS
  • Alzheimer's Association
  • GHR Foundation
  • Eli Lilly and Company
  • NIH HHS
  • Accelerating Medicines Partnership
  • National Institutes of Health
  • National Institute on Aging

Zitieren

APA

Vanderlip, C. R., & Stark, C. E. L. (2026). Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71834

Vancouver

Vanderlip CR, Stark CEL. Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71834

BibTeX
@article{Vanderlip2026,
  author = {Vanderlip, Casey R and Stark, Craig E L},
  title = {Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71834}
}
Kostenlos starten →